# Eupraxia Pharmaceuticals Inc.: financial statements, quarterly

EPRX · Nasdaq · CIK 1581178 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eprx.md) · [Financials](/companies/eprx/financials.md) · [Filings](/companies/eprx/filings.md) · [Insiders](/companies/eprx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eprx/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2021-12-31) | period not labelled (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [18.3](/filings/0001193125-24-083584.md) | [19.3](/filings/0001193125-25-059352.md) | [33.1](/filings/0001193125-26-104765.md) | [80.6](/filings/0001193125-26-104765.md) |
| Current assets | $m | not reported | [18.6](/filings/0001193125-24-083584.md) | [19.8](/filings/0001193125-25-059352.md) | [34.4](/filings/0001193125-26-104765.md) | [85.1](/filings/0001193125-26-104765.md) |
| Total assets | $m | not reported | [19.1](/filings/0001193125-24-083584.md) | [20.3](/filings/0001193125-25-059352.md) | [34.9](/filings/0001193125-26-104765.md) | [86.2](/filings/0001193125-26-104765.md) |
| Current liabilities | $m | not reported | [3.1](/filings/0001193125-24-083584.md) | [19.4](/filings/0001193125-25-059352.md) | [3.1](/filings/0001193125-26-104765.md) | [5.6](/filings/0001193125-26-104765.md) |
| Total liabilities | $m | not reported | [11.9](/filings/0001193125-24-083584.md) | [19.4](/filings/0001193125-25-059352.md) | [3.1](/filings/0001193125-26-104765.md) | [5.7](/filings/0001193125-26-104765.md) |
| Shareholders' equity | $m | [15.1](/filings/0001193125-24-083584.md) | [7.8](/filings/0001193125-24-083584.md) | [2.2](/filings/0001193125-25-059352.md) | [33.4](/filings/0001193125-26-104765.md) | [82.0](/filings/0001193125-26-104765.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

Shares outstanding: 35,641,603 at 2024-12-31, from the cover of the [40-F filed 2025-03-20](/filings/0001193125-25-059352.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.